

Company registration number: 04019402

Dyodelta Biosciences Limited

Unaudited filleted financial statements

30 June 2021



Dyodelta Biosciences Limited

Contents

	Page
Statement of financial position	1 - 2
Statement of changes in equity	3
Notes to the financial statements	4 - 5

Dyodelta Biosciences Limited

**Statement of financial position
30 June 2021**

	Note	2021 £	£	2020 £	£
Current assets					
Debtors	4	11,645		9,400	
Cash at bank and in hand		110,960		31,616	
		<u>122,605</u>		<u>41,016</u>	
Creditors: amounts falling due within one year	5	<u>(68,917)</u>		<u>(53,852)</u>	
Net current assets/(liabilities)			53,688		(12,836)
Total assets less current liabilities			<u>53,688</u>		<u>(12,836)</u>
Net assets/(liabilities)			<u>53,688</u>		<u>(12,836)</u>
Capital and reserves					
Called up share capital			5,000		5,000
Profit and loss account			<u>48,688</u>		<u>(17,836)</u>
Shareholders funds/(deficit)			<u>53,688</u>		<u>(12,836)</u>

For the year ending 30 June 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

The notes on pages 4 to 5 form part of these financial statements.

Dyodelta Biosciences Limited

Statement of financial position (continued)
30 June 2021

These financial statements were approved by the board of directors and authorised for issue on 21 September 2021, and are signed on behalf of the board by:

A handwritten signature in black ink, consisting of a stylized 'C' followed by a series of loops and a horizontal line.

C.L. Dimitriou
Director

Company registration number: 04019402

The notes on pages 4 to 5 form part of these financial statements.

Dyodelta Biosciences Limited

**Statement of changes in equity
Year ended 30 June 2021**

	Called up share capital £	Profit and loss account £	Total £
At 1 July 2019	5,000	(49,721)	(44,721)
Profit for the year		31,885	31,885
Total comprehensive income for the year	-	31,885	31,885
At 30 June 2020 and 1 July 2020	5,000	(17,836)	(12,836)
Profit for the year		66,524	66,524
Total comprehensive income for the year	-	66,524	66,524
At 30 June 2021	5,000	48,688	53,688

Dyodelta Biosciences Limited

Notes to the financial statements Year ended 30 June 2021

1. General information

The company is a private company limited by shares, registered in England & Wales. The address of the registered office is 33 St James's Square, London, SW1Y 4JS.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. The Triennial review 2017 amendments to the standard have been early adopted.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current tax recognised in the reporting period. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

4. Debtors

	2021	2020
	£	£
Trade debtors	9,726	7,928
Other debtors	1,919	1,472
	<u>11,645</u>	<u>9,400</u>

Dyodelta Biosciences Limited

Notes to the financial statements (continued)
Year ended 30 June 2021

5. Creditors: amounts falling due within one year

	2021	2020
	£	£
Corporation tax	15,245	-
Other creditors	53,672	53,852
	<u>68,917</u>	<u>53,852</u>

6. Controlling party

The company is controlled by the directors.